Literature DB >> 19541720

Clinical characteristics and prognostic factors of pulmonary MALT lymphoma.

R Borie1, M Wislez, G Thabut, M Antoine, A Rabbat, L-J Couderc, I Monnet, H Nunes, F-X Blanc, H Mal, A Bergeron, D Dusser, D Israël-Biet, B Crestani, J Cadranel.   

Abstract

Mucosa-associated lymphoid tissue-derived (MALT) lymphoma, a low grade B-cell extranodal lymphoma, is the most frequent subset of primary pulmonary lymphoma. Our objective was to evaluate the initial extent of disease and to analyse the characteristics and long-term outcome of these patients. All chest and pathological departments of teaching hospitals in Paris were contacted in order to identify patients with a histological diagnosis of primary pulmonary lymphoma of the MALT subtype. 63 cases were identified. The median age was 60 yrs. 36% of cases had no symptoms at diagnosis. 46% of patients had at least one extrapulmonary location of lymphoma. The estimated 5- and 10-yr overall survival rates were 90% and 72%, respectively. Only two of the nine observed deaths were related to lymphoma. Age and performance status were the only two adverse prognostic factors for survival. Extrapulmonary location of lymphoma was not a prognostic factor for overall survival or for progression-free survival. Treatment with cyclophosphamide or anthracycline was associated with shorter progression-free survival, when compared with chlorambucil. The survival data confirm the indolent nature of pulmonary MALT lymphoma. Better progression-free survival was observed with chlorambucil when compared with cyclophosphamide or anthracycline.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19541720     DOI: 10.1183/09031936.00039309

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  50 in total

1.  Diagnostic and prognostic factors for patients with primary pulmonary non-Hodgkin's lymphoma: A 16-year single-center retrospective study.

Authors:  Jiang Qian; Dong-Lan Luo; Jin-E Zhang; Wen-Yu Li; Xing-Lin Gao; Xiang-Feng Fang; Hong An; Jun-Liang Deng; Qiong Li; Jian Wu
Journal:  Oncol Lett       Date:  2019-06-12       Impact factor: 2.967

2.  Primary pulmonary NK/T-cell lymphoma: A case report and literature review.

Authors:  Yajuan Qiu; Junna Hou; Dexun Hao; Dandan Zhang
Journal:  Mol Clin Oncol       Date:  2018-04-24

3.  A Case of Pulmonary MALT Lymphoma Arising from Lymphocytic Interstitial Pneumonitis.

Authors:  Ki Hoon Park; Soon Seog Kwon; Myung Hee Chung; Jeana Kim; Hee Jung Lee; Ji-Won Min; Yong Hyun Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-08-31

4.  Enhancing the differentiation of pulmonary lymphoma and fungal pneumonia in hematological patients using texture analysis in 3-T MRI.

Authors:  Damon Kim; Thomas Elgeti; Tobias Penzkofer; Ingo G Steffen; Laura J Jensen; Stefan Schwartz; Bernd Hamm; Sebastian N Nagel
Journal:  Eur Radiol       Date:  2020-08-21       Impact factor: 5.315

5.  Pulmonary MALT Lymphoma in Patients with Sjögren's Syndrome.

Authors:  Ralph Yachoui; Chady Leon; Kajal Sitwala; Mazen Kreidy
Journal:  Clin Med Res       Date:  2017-05-09

6.  Effects of microvascular density on primary pulmonary non-Hodgkin's lymphoma (PPL).

Authors:  Maopeng Yang; Shu Zhao; Xaiosan Zhang; Xiaohong Wang; Minghui Zhang; Yan Wang; Qingyuan Zhang
Journal:  Tumour Biol       Date:  2012-08-09

7.  Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma.

Authors:  Ikue Okamura; Hisao Imai; Keita Mori; Kazuto Ogura; Atsushi Isoda; Keichiro Mihara; Morio Matsumoto; Ryusei Saito; Toshiaki Takahashi; Takashi Ikeda
Journal:  Int J Hematol       Date:  2014-11-07       Impact factor: 2.490

8.  Prolonged complete remission in a primary MALT lymphoma of the lung after rituximab monotherapy.

Authors:  M D Diamantidis; S Chatzileontiadou; D Pantelidou; M Papaioannou
Journal:  Hippokratia       Date:  2017 Apr-Jun       Impact factor: 0.471

9.  Significance of imaging and clinical features in the differentiation between primary and secondary pulmonary lymphoma.

Authors:  Yuhao Dong; Miaoyu Zeng; Bin Zhang; Lujun Han; Entao Liu; Zhouyang Lian; Jing Liu; Changhong Liang; Shuixing Zhang
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

10.  Comparisons of Surgery and/or Chemotherapy in the Treatment of Primary Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma.

Authors:  Bo Wang; Chengwei Zhang; Bin Wang; Lianbin Zhang
Journal:  Ann Thorac Cardiovasc Surg       Date:  2014-08-29       Impact factor: 1.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.